👉 Watch more ▶ https://bit.ly/finite-future
------------------------------
TRANSCRIPT
A new drug called rusfertide has shown promise in treating polycythemia vera, a rare blood cancer.
In a clinical trial involving 70 patients, rusfertide effectively lowered excess red blood cell production, reducing the need for phlebotomy and improving quality of life. Led by researchers from the Icahn School of Medicine at Mount Sinai, the trial demonstrated favorable safety and sustained control of hematocrit levels.
Rusfertide, mimicking the hormone hepcidin, offers hope for better management of polycythemia vera and is now undergoing phase 3 trials for further validation and exploration in other blood disorders.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2308809?query=featured_home
------------------------------
ABOUT
Finite Future brings you the latest future technology and science news that can disrupt the world we live in – for better or worse.
• We are concerned about the future of humanity.
• We care about our planet.
• We want to make the world a better place.
You are here because you share the same values. Please become a Supporter!
👉 Subscribe ▶ https://bit.ly/FF-subscribe
A new drug called rusfertide has shown promise inÂ
treating polycythemia vera, a rare blood cancer. In a clinical trial involving 70 patients,Â
rusfertide effectively lowered excess red blood cell production, reducing the need forÂ
phlebotomy and improving quality of life. Led by researchers from the IcahnÂ
School of Medicine at Mount Sinai, the trial demonstrated favorable safetyÂ
and sustained control of hematocrit levels. Rusfertide, mimicking the hormone hepcidin, offers hope for better mana
gement ofÂ
polycythemia vera and is now undergoing phase 3 trials for further validationÂ
and exploration in other blood disorders.
Comments